What Can Cause a False Positive Drug Test for Suboxone?

A false positive drug test for Suboxone almost always traces back to one of a few known culprits: tramadol is the best-documented, followed by the antipsychotics amisulpride and sulpride, all of which can cross-react with the buprenorphine immunoassay and produce a positive screen when no buprenorphine is present.¹ The rate is roughly 1 in 100 screens on the most widely used assay, and the fix is the same in nearly every case: a confirmatory lab test that identifies the exact molecule in the sample rather than one that looks similar.

Why Immunoassays Get It Wrong

Buprenorphine does not appear on standard opiate panels. Labs have to add a separate, buprenorphine-specific immunoassay to the testing panel for it to show up at all.² That assay works by recognizing molecular shape, not chemical identity. When another drug in the urine has a shape close enough to buprenorphine, the assay flags it as positive. That shape-matching is where every false positive on this test comes from.

The second-stage confirmatory test uses liquid chromatography-tandem mass spectrometry, or LC-MS/MS. It identifies the precise chemical present in the sample rather than guessing from shape, and false positives essentially disappear at this stage.³ If your positive result came from an immunoassay screen alone, confirmatory testing is the single most important thing to ask for.

Medications Known to Cause False Positives

Tramadol

Tramadol is a commonly prescribed pain reliever, and it is the most consistently documented cause of a false-positive buprenorphine result. In one study, 7 out of 29 urine samples from patients taking tramadol falsely screened positive for buprenorphine across multiple point-of-care immunoassays and the widely used CEDIA instrument-based assay.³ The problem is worse at lower cutoff thresholds. If you take tramadol and are being tested for buprenorphine, that combination alone can explain a positive result.

Amisulpride and Sulpride

Both amisulpride and sulpride, antipsychotic medications, are listed as known interferents on the buprenorphine immunoassay.¹ If you take either of these and get a positive buprenorphine screen without taking Suboxone, this is the likeliest explanation to raise with your prescriber and the reviewing physician.

How the Assay and Cutoff Change the Odds

The false positive rate depends on which immunoassay the lab runs and what cutoff concentration it uses. The CEDIA buprenorphine assay at a 5 ng/mL cutoff produced a 1.1% false positive rate across more than 2,000 patient samples. Raising the cutoff to 10 ng/mL dropped that rate to 0.3%.¹ If you are being tested regularly and are getting recurring positives while taking a listed cross-reactant, ask the lab which assay it runs and at what cutoff. The answer often explains the pattern.

When a Positive Result Is Not a False Positive

Recent Suboxone use will produce a positive result that is entirely real. Buprenorphine is typically detectable in urine for one to seven days after the last dose, and its main metabolite, norbuprenorphine, can persist for up to 14 days.⁴ Individual metabolism, dose, and hydration shift that window. If you recently stopped Suboxone and test positive within those timeframes, that is the drug doing what it does, not a lab error. Ruling this out first saves time and preserves credibility when you challenge results that really are wrong.

How to Challenge a False Positive

Under federally regulated drug testing programs, including those covering transportation workers, federal employees, and many private employers who follow Department of Transportation protocols, several protections apply automatically. Miss any of them and the result stands.

Answer the Medical Review Officer

Before any positive immunoassay result is reported to your employer, it goes to a Medical Review Officer, a licensed physician trained in substance abuse testing. Federal regulation requires the MRO to contact you directly and hold a confidential verification interview.⁵ During that call, you can present a legitimate medical explanation, such as a Suboxone prescription or a prescription for tramadol or one of the antipsychotics that cause interference. The MRO has discretion to give you up to five additional days to produce supporting documentation like pharmacy records or a letter from your prescriber.⁶

The MRO is required to make at least three contact attempts over a 24-hour period. If you do not respond, the result is verified as positive by default.⁵ Answer the phone.

Request a Split Specimen Test Within 72 Hours

Every urine specimen collected under DOT rules is split into two vials at collection. Once the MRO notifies you of a verified positive, you have 72 hours from that notification to request testing of the second vial at a different laboratory.⁷ The request can be verbal or written. Your employer must cover the upfront cost of the split test, though it may seek reimbursement from you afterward.⁸ A negative split specimen throws the original result into serious question. The 72-hour deadline is strict, so make the request the moment you get the notification.

Insist on Confirmatory LC-MS/MS Testing

Point-of-care testing, clinical office screens, and some probation programs stop at the immunoassay stage. If your positive result came from a screen alone, ask for LC-MS/MS confirmation. It identifies the exact chemical present and separates buprenorphine from cross-reactants that only look similar.

Document Everything You Take

Give the MRO or reviewing physician a complete list of your prescription medications, over-the-counter drugs, and dietary supplements. Tramadol, amisulpride, and sulpride are the ones to flag by name if you take them. Pharmacy dispensing records and a letter from your prescriber carry more weight than a verbal explanation and are worth gathering before the verification interview if you can.

If You Do Have a Suboxone Prescription

The Americans with Disabilities Act treats prescribed Suboxone taken as directed as legal medication, not illegal drug use.⁹ Employers generally cannot refuse to hire you, fire you, or take other adverse action because a drug test reflects your prescribed medication, unless you cannot perform the job safely and effectively.¹⁰ Parallel protections cover prisons and jails run by state or local governments, recovery housing under the ADA and Fair Housing Act, and any program receiving federal funding under Section 504 of the Rehabilitation Act.

Two limits are worth knowing. The ADA does not protect anyone currently using drugs illegally, and it does not enforce itself. Current prescription documentation, kept accessible, is what turns the legal protection into a practical one when a test result lands on someone’s desk.

Outside federally regulated testing, the MRO review and split-specimen rights may not apply. In that setting, an independent confirmatory LC-MS/MS test is the strongest tool you have, and its cost is modest compared to what an unchallenged positive can cost you.

1
NCBI PMC. Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids
2
National Center for Biotechnology Information (NCBI). Toxicologic Testing for Opiates: Understanding False-Positive and False-Negative Test Results
3
PubMed. Effect of tramadol use on three point-of-care and one instrument-based immunoassays for buprenorphine
4
PMC. Buprenorphine, Norbuprenorphine, and Naloxone Levels in Adulterated Urine Samples
5
eCFR. 49 CFR Part 40 Subpart G – Medical Review Officers and Verification Process
6
eCFR. 49 CFR 40.137 – MRO Verification Interview Procedures
7
eCFR. 49 CFR 40.171 – How does an employee request a test of a split specimen?
8
eCFR. 49 CFR 40.153 – How does the MRO notify employees of their right to a test of a split specimen?
9
ADA.gov. Opioid Use Disorder
10
ADA.gov. The ADA and Opioid Use Disorder: Combating Discrimination